Credit rating agency, India Rating & Research (Ind- Ra) has affirmed ‘A’ rating with a ‘Stable’ outlook to long term bank facilities to Claris Lifesciences. Since all the working capital and term loans have been transferred to Claris Injectables (CIL), the agency has withdrawn the ratings of the short term / long term loan instruments of CLL. However the same ratings have been assigned to CIL instruments.
Claris Lifesciences is one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.
